Cutaneous Adverse Effects of Targeted Therapies

The document discusses the emergence of targeted therapies for skin cancers like metastatic melanoma and basal cell carcinoma, focusing on the cutaneous adverse effects associated with these treatments. It highlights that inhibitors targeting the PI3K-AKT-mTOR and RAS-RAF-MEK-ERK pathways, which are implicated in various cancers, frequently cause skin toxicities. The document also mentions hedgehog signaling pathway inhibitors and immunotherapies as having similar dermatologic side effects. It emphasizes the importance of dermatologists in managing these skin-related issues, given the increasing use of these targeted therapies. The article is part of a continuing medical education series and aims to educate on the skin toxicities, their prevalence, and the clinical significance of both on-target and off-target effects of these cancer treatments.